MAPT and Schnyder corneal dystrophy: Concerning p-tau biomarkers, plasma p-tau181 has been shown by numerous studies to accurately distinguish between SCD patients with and without Alzheimer’s disease pathology (Karikari et al., 2020; Palmqvist et al., 2021; Thomas et al., 2021; Gerards et al., 2022; Giacomucci et al., 2023).